Drug Profile
SPN 803
Alternative Names: SPN803Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Supernus Pharmaceuticals
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Parkinson's-disease in USA
- 31 Dec 2008 Phase-I clinical trials in Parkinson's disease in USA (unspecified route)